Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors

LESSONS LEARNED. Ramucirumab was well tolerated in Chinese patients with advanced solid tumors, and adverse events were manageable in this study. Pharmacokinetics characteristics in Chinese patients were similar to those in other populations. Immunogenicity was not detected. No efficacy conclusion c...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncologist
Main Authors: Cao, Junning, Ji, Dongmei, Chen, Zhiyu, Shen, Weina, Wang, Jin, Li, Baoyue, Chi, Haidong, Long, Amanda, Gao, Ling, Li, Jin
Format: Artigo
Sprog:Inglês
Udgivet: AlphaMed Press 2017
Fag:
Clinical Trial Results
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5469595/
https://ncbi.nlm.nih.gov/pubmed/28465370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0137
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker